An observational study in Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-16.
Sponsored by Hospices Civils de Lyon · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Autoimmune Diseases of the Nervous System by Hospices Civils de Lyon — 8 open to participants now, 11 under way, none of them phase 3. Autoimmune Diseases of the Nervous System · Hospices Civils de Lyon.
Among the 22 studies in Autoimmune Diseases of the Nervous System by Hospices Civils de Lyon, this one is the 8th largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2022, is one of 21 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 12th registered.
123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.
Browse Autoimmune Diseases of the Nervous System studies →8 of the 22 studies in Autoimmune Diseases of the Nervous System by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Hospices Civils de Lyon · Sites in France
Ages 18–100
Hospices Civils de Lyon · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
By country, each count listing its studies:
Of the 44 Autoimmune Diseases of the Nervous System studies recruiting now, 27 (61%) set no upper age limit and 11 (25%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 5 started in 2022.
This study's planned enrollment of 180 is above the median of 160 across 57 observational studies indexed under Autoimmune Diseases of the Nervous System.
Median enrollment 3,500 across the 1 interventional studies, 50 across the 21 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hospices Civils de Lyon is the lead sponsor of 1,867 studies on the registry; 448 are open to participants now.
1 of the studies in Autoimmune Diseases of the Nervous System by Hospices Civils de Lyon that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07158229Hospices Civils de LyonLong-term Impact of NMDAR Encephalitis, Level 3 | 2026-11-21 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Autoimmune Diseases of the Nervous System by Hospices Civils de Lyon, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients.
Patient with auto-immune encephalitis suspected and antibody characterized or not.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with well-characterized antibody (HU, YO, RI, CASPR2, NMDAr, GAD, ...)
Biological: Genetic and immunology tests
Patients with atypical antibody
Biological: Genetic and immunology tests
Patients without antibody
Biological: Genetic and immunology tests
This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "Centre de Ressources Biologiques des Hospices Civils de Lyon" (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes.
Correlation between biological results and clinical data
This measure will compare the result of immunological and genetic makers with clinical data of each patient.
Time frame: Through study completion, an average of 1year
Started Feb 2022 (actual). Primary completion is estimated for Feb 2024, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Autoimmune Diseases of the Nervous System →